glp 1 drugs kidney disease Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis SGLT2 vs GLP-1 for Kidney

Although there is no GLP-1RA approved for the treatment of AS, these findings could provide novel approaches for the treatment of AS

Find your perfect match

The phase 2 trial published in the New England Journal of Medicine documented heart rate increases across every dose group

KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use Findings Key Takeaways With the Trump administration recently announcing several high-profile prescription drug pricing deals, the latest polling from KFF suggests that few think it is likely the Trump administrations actions will lower their prescription drug costs, but his base remains more positive

Dose optimization strategies before considering a full reset Before committing to a drug holiday or medication switch, explore whether dose optimization can break the plateau

Association between glycemic status and the risk of Parkinson disease: A nationwide population-based study